{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:43:54Z","timestamp":1788345834620,"version":"build-2803163510"},"reference-count":286,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.thromres.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T12:55:36Z","timestamp":1707224136000},"page":"125-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials"],"prefix":"10.1016","volume":"235","author":[{"given":"Mahda","family":"Delshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Davoodi-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Pourbagheri-Sigaroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Faranoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Abolghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-4920","authenticated-orcid":false,"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0005","first-page":"2386","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"26","key":"10.1016\/j.thromres.2024.02.005_bb0010","first-page":"6511","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"22","key":"10.1016\/j.thromres.2024.02.005_bb0015","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.hoc.2007.06.007","article-title":"Immune thrombocytopenic purpura","volume":"21","author":"Psaila","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.thromres.2024.02.005_bb0030","article-title":"Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently?","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0035","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J. Lab. Clin. Med."},{"issue":"15","key":"10.1016\/j.thromres.2024.02.005_bb0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","article-title":"Mechanisms of response to treatment in autoimmune thrombocytopenic purpura","volume":"320","author":"Gernsheimer","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.20309","article-title":"Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP)","volume":"78","author":"Davoren","year":"2005","journal-title":"Am. J. Hematol."},{"issue":"1\u20132","key":"10.1016\/j.thromres.2024.02.005_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0609.1996.tb00298.x","article-title":"Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA","volume":"56","author":"Stockelberg","year":"1996","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0055","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.hoc.2009.08.008","article-title":"Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production","volume":"23","author":"McMillan","year":"2009","journal-title":"Hematology\/Oncology Clinics."},{"key":"10.1016\/j.thromres.2024.02.005_bb0060","series-title":"Reid DM","author":"He","year":"1994"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0065","first-page":"1819","article-title":"Platelet-associated anti\u2013GPIIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura recognizing epitopes close to the ligand-binding site of glycoprotein (GP) IIb","volume":"98","author":"Kosugi","year":"2001","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0070","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/art.10420","article-title":"Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2024.02.005_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.thromres.2018.08.021","article-title":"Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO","volume":"170","author":"Jing","year":"2018","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0085","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3324\/haematol.12889.","article-title":"Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies","volume":"93","author":"Zhao","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0090","first-page":"1388","article-title":"Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation","volume":"100","author":"Roark","year":"2002","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0095","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri856","article-title":"Roles of fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0100","doi-asserted-by":"crossref","unstructured":"Roth R, Nakamura T, Mamula MJ. B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. Journal of immunology (Baltimore, Md: 1950). 1996;157(7):2924\u201331.","DOI":"10.4049\/jimmunol.157.7.2924"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-065X.1986.tb01168.x","article-title":"Organ-specific autoimmunity: a 1986 overview","volume":"94","author":"Bottazzo","year":"1986","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0110","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.192.4.475","article-title":"B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell\u2013deficient mice results in T helper cell type 1 deviation","volume":"192","author":"Moulin","year":"2000","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.thromres.2024.02.005_bb0120","first-page":"4394","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"16","key":"10.1016\/j.thromres.2024.02.005_bb0125","first-page":"3318","article-title":"Defective regulatory B-cell compartment in patients with immune thrombocytopenia","volume":"120","author":"Li","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0130","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.4049\/jimmunol.168.10.4837","article-title":"Evidence for a dual mechanism for IL-10 suppression of TNF-\u03b1 production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-\u03baB in primary human macrophages","volume":"168","author":"Denys","year":"2002","journal-title":"The Journal of Immunology."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/thx.51.2.143","article-title":"Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes","volume":"51","author":"Armstrong","year":"1996","journal-title":"Thorax"},{"issue":"22","key":"10.1016\/j.thromres.2024.02.005_bb0140","first-page":"4639","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0145","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0002-9343(99)00054-6","article-title":"Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura","volume":"106","author":"Louwes","year":"1999","journal-title":"Am. J. Med."},{"issue":"03","key":"10.1016\/j.thromres.2024.02.005_bb0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678732","article-title":"Pathophysiology of autoimmune thrombocytopenia: current insight with a focus on thrombopoiesis","volume":"39","author":"Marini","year":"2019","journal-title":"H\u00e4mostaseologie"},{"issue":"23","key":"10.1016\/j.thromres.2024.02.005_bb0155","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1001\/jama.1978.03280500056020","article-title":"Antibody against megakaryocytes in idiopathic thrombocytopenic purpura","volume":"239","author":"McMillan","year":"1978","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0160","first-page":"1951","article-title":"Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation","volume":"93","author":"Takahashi","year":"1999","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0165","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0170","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.02.005_bb0175","article-title":"Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia","volume":"9(1):2208","author":"Grodzielski","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2024.02.005_bb0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fped.2016.00102","article-title":"The centenary of immune thrombocytopenia\u2013part 1: revising nomenclature and pathogenesis","volume":"4","author":"Consolini","year":"2016","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/107602960200800110","article-title":"The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review","volume":"8","author":"Jubelirer","year":"2002","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0190","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/09537104.2012.669508","article-title":"A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production","volume":"24","author":"Perdomo","year":"2013","journal-title":"Platelets"},{"issue":"20","key":"10.1016\/j.thromres.2024.02.005_bb0195","first-page":"4307","article-title":"Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood, the journal of the American society of","volume":"116","author":"Yang","year":"2010","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0200","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"Li","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1034\/j.1600-0609.2003.00069.x","article-title":"Investigation of megakaryocyte apoptosis in children with acute and chronic idiopathic thrombocytopenic purpura","volume":"70","author":"U\u00e7ar","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0210","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and Para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0215","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/09537104.2018.1475637","article-title":"Megakaryocyte apoptosis in immune thrombocytopenia","volume":"29","author":"Vrbensky","year":"2018","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1983.00201.x-i1","article-title":"Fate of senescent megakaryocytes in the bone marrow","volume":"53","author":"Radley","year":"1983","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.thromres.2024.02.005_bb0225","first-page":"5479","article-title":"Heterozygous ITGA2B R995W mutation inducing constitutive activation of the \u03b1IIb\u03b23 receptor affects proplatelet formation and causes congenital macrothrombocytopenia","volume":"117","author":"Kunishima","year":"2011","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb0230","article-title":"Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome","volume":"94(6):800","author":"Strassel","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14977","article-title":"Autoantibodies in immune thrombocytopenia affect the physiological interaction between megakaryocytes and bone marrow extracellular matrix proteins","volume":"183","author":"Grodzielski","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0240","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.12832","article-title":"Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count","volume":"165","author":"Lev","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0245","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.2014.115634","article-title":"Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro","volume":"100","author":"Iraqi","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0250","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2003-12-4398","article-title":"Differential regulation of actin stress fiber assembly and proplatelet formation by \u03b12\u03b21 integrin and GPVI in human megakaryocytes","volume":"104","author":"Sabri","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0255","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3324\/haematol.2019.236117","article-title":"Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan","volume":"106","author":"Marini","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0260","first-page":"1499","article-title":"Recognition of highly restricted regions in the \u03b2-propeller domain of \u03b1IIb by platelet-associated anti-\u03b1IIb\u03b23 autoantibodies in primary immune thrombocytopenia","volume":"120","author":"Kiyomizu","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb0265","series-title":"Reid DM","author":"He","year":"1995"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0270","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2005.01379.x","article-title":"Platelet GPIb-IX-V-dependent signaling","volume":"3","author":"Ozaki","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0275","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-04-1257","article-title":"Integrins: dynamic scaffolds for adhesion and signaling in platelets","volume":"104","author":"Shattil","year":"2004","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.thromres.2024.02.005_bb0280","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/S0021-9258(17)33044-2","article-title":"II. Purification and characterization","volume":"251","author":"Okumura","year":"1976","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2024.02.005_bb0285","doi-asserted-by":"crossref","unstructured":"Solum NO, Hagen I, Filion-Myklebust C, Stabaek T. Platelet glycocalicin. Its membrane association and solubilization in aqueous media. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1980;597(2):235\u201346.","DOI":"10.1016\/0005-2736(80)90102-9"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0290","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/nm.2030","article-title":"Dual roles for hepatic lectin receptors in the clearance of chilled platelets","volume":"15","author":"Rumjantseva","year":"2009","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0295","first-page":"3249","article-title":"Galactosylation does not prevent the rapid clearance of long-term, 4 C-stored platelets","volume":"111","author":"Wandall","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0300","first-page":"1645","article-title":"Role of sialic acid for platelet life span: exposure of \u03b2-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor\u2013expressing liver macrophages and hepatocytes","volume":"114","author":"S\u00f8rensen","year":"2009","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0305","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat. Commun."},{"issue":"31","key":"10.1016\/j.thromres.2024.02.005_bb0310","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1707662114","article-title":"Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0315","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190723","article-title":"Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets","volume":"217","author":"Deppermann","year":"2020","journal-title":"Journal of Experimental Medicine."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0320","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s41418-021-00797-w","article-title":"Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice","volume":"28","author":"Jiang","year":"2021","journal-title":"Cell Death & Differentiation."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0325","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bjh.16459","article-title":"Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation","volume":"189","author":"Monz\u00f3n Manzano","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5503","key":"10.1016\/j.thromres.2024.02.005_bb0330","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0335","first-page":"2939","article-title":"Helicobacter pylori eradication shifts monocyte Fc\u03b3 receptor balance toward inhibitory Fc\u03b3RIIB in immune thrombocytopenic purpura patients","volume":"118","author":"Asahi","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0340","first-page":"2061","article-title":"High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fc\u03b3 receptors on monocytes in patients with primary immune thrombocytopenia. Blood, the journal of the American society of","volume":"117","author":"Liu","year":"2011","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160563","article-title":"Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies","volume":"11","author":"Goette","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0350","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.exphem.2006.03.009","article-title":"Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes","volume":"34","author":"Catani","year":"2006","journal-title":"Exp. Hematol."},{"issue":"07","key":"10.1016\/j.thromres.2024.02.005_bb0355","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH13-10-0873","article-title":"Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia","volume":"112","author":"Rom\u00e1n","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0360","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.3892\/mmr.2017.6901","article-title":"MicroRNA profiling of platelets from immune thrombocytopenia and target gene prediction","volume":"16","author":"Deng","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"25","key":"10.1016\/j.thromres.2024.02.005_bb0365","first-page":"5989","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0370","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2352-3026(20)30215-5","article-title":"Endothelial cells orchestrate COVID-19 coagulopathy","volume":"7","author":"O\u2019Sullivan","year":"2020","journal-title":"The Lancet Haematology."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0375","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/09537104.2019.1624706","article-title":"The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2019","journal-title":"Platelets"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0380","first-page":"1976","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"14","key":"10.1016\/j.thromres.2024.02.005_bb0385","first-page":"2755","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.005_bb0390","doi-asserted-by":"crossref","first-page":"15978","DOI":"10.1074\/jbc.274.23.15978","article-title":"Identification and characterization of a novel cytokine, THANK, aTNF homologue that ActivatesApoptosis, nuclear factor-\u03baB, and c-Jun NH2-terminal kinase","volume":"274","author":"Mukhopadhyay","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"5425","key":"10.1016\/j.thromres.2024.02.005_bb0395","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0400","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.2006.06431.x","article-title":"High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"136","author":"Emmerich","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0410","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/08916930802397848","article-title":"BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura","volume":"42","author":"Zhou","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.thromres.2024.02.005_bb0415","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10875-009-9303-y","article-title":"High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia","volume":"29","author":"Zhu","year":"2009","journal-title":"J. Clin. Immunol."},{"issue":"26","key":"10.1016\/j.thromres.2024.02.005_bb0420","first-page":"5362","article-title":"The effects of BAFF and BAFF-R-fc fusion protein in immune thrombocytopenia. Blood, the journal of the American society of","volume":"114","author":"Zhu","year":"2009","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0609.2010.01534.x","article-title":"TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura","volume":"86","author":"Yu","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0430","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s10875-010-9443-0","article-title":"Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients","volume":"30","author":"Zhou","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0435","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.gene.6363923","article-title":"Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis","volume":"3","author":"Kawasaki","year":"2002","journal-title":"Genes & Immunity."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0440","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2005.02.7938","article-title":"Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders","volume":"24","author":"Novak","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0445","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"10320","key":"10.1016\/j.thromres.2024.02.005_bb0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.thromres.2024.02.005_bb0455","author":"Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1) [updated January 8"},{"key":"10.1016\/j.thromres.2024.02.005_bb0460","author":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2) [updated December 22"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0465","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase IIb trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0470","doi-asserted-by":"crossref","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0475","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0480","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"issue":"22","key":"10.1016\/j.thromres.2024.02.005_bb0485","first-page":"3033","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb0490","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.thromres.2024.02.005_bb0500","doi-asserted-by":"crossref","unstructured":"Tsykunova G, Holme PA, Tran HTT, Tvedt THA, Munthe L, Michel M, et al. PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY). HemaSphere. 2022;6(Suppl).","DOI":"10.1097\/01.HS9.0000852076.33574.89"},{"key":"10.1016\/j.thromres.2024.02.005_bb0505","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/blood-2021-151410","article-title":"Daratumumab as a treatment for adult immune thrombocytopenia: a phase II study with safety run-in (the DART study)","volume":"138","author":"Tsykunova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.02.005_bb0510","article-title":"CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model","volume":"198(1_Supplement):127.17-.17","author":"Smithson","year":"2017","journal-title":"The Journal of Immunology."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0515","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0520","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/molecules21070927","article-title":"Computational approaches for the discovery of human proteasome inhibitors: an overview","volume":"21","author":"Guedes","year":"2016","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0525","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0530","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proceedings of the Japan Academy, Series B."},{"key":"10.1016\/j.thromres.2024.02.005_bb0535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Kish-Trier","year":"2013","journal-title":"Annu. Rev. Biophys."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0540","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0545","doi-asserted-by":"crossref","unstructured":"Kimura H, Caturegli P, Takahashi M, Suzuki K. New insights into the function of the immunoproteasome in immune and nonimmune cells. J. Immunol. Res. 2015;2015.","DOI":"10.1155\/2015\/541984"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0550","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri2687","article-title":"Proteasomes in immune cells: more than peptide producers?","volume":"10","author":"Groettrup","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0555","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for refractory immune-mediated thrombocytopenia purpura (ITP)","volume":"25","author":"Beckman","year":"2018","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.thromres.2024.02.005_bb0560","series-title":"Bortezomib for ITP: First Report of Successful Treatment of Refractory ITP in a Patient with Otherwise Asymptomatic Monoclonal Gammopathy","author":"Lazaryan","year":"2010"},{"issue":"S1","key":"10.1016\/j.thromres.2024.02.005_bb0565","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5045\/br.2022.2022038","article-title":"Recent advances in treatments of adult immune thrombocytopenia","volume":"57","author":"Kim","year":"2022","journal-title":"Blood research."},{"issue":"24","key":"10.1016\/j.thromres.2024.02.005_bb0570","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.thromres.2024.02.005_bb0575","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10875-012-9768-y","article-title":"The immunologic functions of the neonatal fc receptor for IgG","volume":"33","author":"Rath","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0580","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0585","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0590","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jps.20828","article-title":"Pharmacokinetic\/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia","volume":"96","author":"Deng","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.thromres.2024.02.005_bb0595","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0600","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.7150\/thno.53961","article-title":"Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"issue":"5787","key":"10.1016\/j.thromres.2024.02.005_bb0605","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0610","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","article-title":"Controlled tetra-fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.thromres.2024.02.005_bb0615","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood-2019-125993","article-title":"Hyper-sialylated IgG M254, an innovative therapeutic candidate, evaluated in healthy volunteers and in patients with immune thrombocytopenia purpura: safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"134","author":"Arroyo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0620","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"48","key":"10.1016\/j.thromres.2024.02.005_bb0625","doi-asserted-by":"crossref","first-page":"17110","DOI":"10.1073\/pnas.1417717111","article-title":"An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein","volume":"111","author":"Seijsing","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0630","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0635","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0640","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0645","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0650","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2023-189125","article-title":"Time to achieve Platelet count response after intravenous Efgartigimod in adults with primary immune thrombocytopenia: a phase 3, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV)","volume":"142","author":"Broome","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.02.005_bb0655","doi-asserted-by":"crossref","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, et al., editors. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs; 2018: Taylor & Francis.","DOI":"10.1080\/19420862.2018.1505464"},{"issue":"8877","key":"10.1016\/j.thromres.2024.02.005_bb0660","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc\u03b3 fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debr\u00e9","year":"1993","journal-title":"The Lancet."},{"key":"10.1016\/j.thromres.2024.02.005_bb0665","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00320302","article-title":"Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?","volume":"50","author":"Augener","year":"1985","journal-title":"Blut"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0670","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.4049\/jimmunol.170.6.3134","article-title":"Human IgG2 can form covalent dimers","volume":"170","author":"Yoo","year":"2003","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.005_bb0675","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IgG2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.005_bb0680","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.thromres.2024.02.005_bb0685","doi-asserted-by":"crossref","first-page":"10789","DOI":"10.1074\/jbc.RA118.007134","article-title":"The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions","volume":"294","author":"Hui","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.thromres.2024.02.005_bb0690","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0695","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121905","article-title":"A recombinant human IgG1 fc multimer designed to mimic the active fraction of IVIG in autoimmunity","volume":"4","author":"Zhang","year":"2019","journal-title":"JCI insight."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0700","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2016001917","article-title":"A fully recombinant human IgG1 fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b","volume":"1","author":"Zhou","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.02.005_bb0705","article-title":"Elucidating the interplay between IgG-fc valency and Fc\u03b3R activation for the design of immune complex inhibitors","volume":"8(365):365ra158-365ra158","author":"Ortiz","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.thromres.2024.02.005_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.617767","article-title":"Engineered IgG1-fc molecules define Valency control of cell surface Fc\u03b3 receptor inhibition and activation in endosomes","volume":"11","author":"Bailey","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0715","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/s41598-017-17255-8","article-title":"Multivalent fc \u03b3-receptor engagement by a hexameric fc-fusion protein triggers fc \u03b3-receptor internalisation and modulation of fc \u03b3-receptor functions","volume":"7","author":"Qureshi","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0720","first-page":"1263","article-title":"Desialylation accelerates platelet clearance after refrigeration and initiates GPIb\u03b1 metalloproteinase-mediated cleavage in mice","volume":"119","author":"Jansen","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0725","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0730","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1021\/jm201271b","article-title":"Discovery and development of spleen tyrosine kinase (SYK) inhibitors","volume":"55","author":"Singh","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0735","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb0740","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ajhp\/zxz052","article-title":"Fostamatinib for the treatment of immune thrombocytopenia in adults","volume":"76","author":"Moore","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0745","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.thromres.2024.02.005_bb0750","first-page":"2027","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0755","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MBC.0000000000000749","article-title":"Ibrutinib-related bleeding: pathogenesis, clinical implications and management","volume":"29","author":"Aguilar","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0760","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"The Journal of Immunology."},{"key":"10.1016\/j.thromres.2024.02.005_bb0765","first-page":"76","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.thromres.2024.02.005_bb0770","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcimb.2012.00016","article-title":"Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials","volume":"2","author":"Bagnoli","year":"2012","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0775","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.005_bb0780","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1084\/jem.20141404","article-title":"Staphylococcus aureus infection induces protein A\u2013mediated immune evasion in humans","volume":"211","author":"Pauli","year":"2014","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0785","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20020552","article-title":"Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin","volume":"197","author":"Goodyear","year":"2003","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0790","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14985","article-title":"A highly purified form of staphylococcal protein a alleviates murine immune thrombocytopenia (ITP)","volume":"183","author":"Kapur","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0795","article-title":"Noninvasive low-level laser therapy for thrombocytopenia","volume":"8(349):349ra101-349ra101","author":"Zhang","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0800","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/09537104.2014.935315","article-title":"Mitoquinone restores platelet production in irradiation-induced thrombocytopenia","volume":"26","author":"Ramsey","year":"2015","journal-title":"Platelets"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0805","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/bjh.17872","article-title":"Novel therapies for immune thrombocytopenia","volume":"196","author":"Kuter","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0810","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1054\/blre.2001.0172","article-title":"Immune pathophysiology of autoimmune thrombocytopenic purpura","volume":"16","author":"Semple","year":"2002","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2024.02.005_bb0815","series-title":"Determination of Platelet Antigens and Glycoproteins in the Human Fetus","author":"Gruel","year":"1986"},{"key":"10.1016\/j.thromres.2024.02.005_bb0820","series-title":"Bradley AJ","author":"Filion","year":"1996"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0825","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.1991.tb00598.x","article-title":"Peripheral tolerance in transgenic mice: tolerance to class II MHC and non-MHC transgene antigens","volume":"122","author":"Lo","year":"1991","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.005_bb0830","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.4049\/jimmunol.171.12.6323","article-title":"The regulatory T cell family: distinct subsets and their interrelations","volume":"171","author":"Jonuleit","year":"2003","journal-title":"The Journal of Immunology."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0835","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI4238","article-title":"Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody","volume":"102","author":"Kuwana","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0840","first-page":"914","article-title":"Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura","volume":"90","author":"Wang","year":"2005","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb0845","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2003-07-2268","article-title":"Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response","volume":"103","author":"Panitsas","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0850","first-page":"669","article-title":"Profiles of type 1 and type 2 T cells in chronic idiopathic thrombocytopenic purpura","volume":"86","author":"Wang","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026522","article-title":"Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia","volume":"6","author":"Hu","year":"2011","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0860","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14661","article-title":"Numerical and functional defects in CD8+ CD28\u2212 T-suppressor lymphocytes from patients with primary immune thrombocytopenia","volume":"178","author":"Li","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0865","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10875-009-9353-1","article-title":"Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia","volume":"30","author":"Zhu","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0870","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.thromres.2006.09.008","article-title":"Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura","volume":"120","author":"Sakakura","year":"2007","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0875","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.humimm.2012.04.015","article-title":"Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia","volume":"73","author":"Hu","year":"2012","journal-title":"Hum. Immunol."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb0880","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3324\/haematol.2009.007823","article-title":"Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura","volume":"94","author":"Zhang","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb0885","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1538-7836.2012.04757.x","article-title":"Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura","volume":"10","author":"Feng","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb0890","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1038\/s41598-019-45264-2","article-title":"High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4\u201328\/IGHJ4 gene in primary immune thrombocytopenia","volume":"9","author":"Hirokawa","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2024.02.005_bb0895","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2019.03.005","article-title":"Aberrant expression of microRNA in CD4+ cells contributes to Th17\/Treg imbalance in primary immune thrombocytopenia","volume":"177","author":"Hua","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.02.005_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102701","article-title":"Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: implications in DNA repair and immune responses","volume":"83","author":"Mandke","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.thromres.2024.02.005_bb0905","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1050285","article-title":"Transcription factor IRF4 dysfunction affects the immunosuppressive function of treg cells in patients with primary immune thrombocytopenia","volume":"2019","author":"Tang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.thromres.2024.02.005_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154853","article-title":"Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP)","volume":"125","author":"Zhao","year":"2020","journal-title":"Cytokine"},{"issue":"24","key":"10.1016\/j.thromres.2024.02.005_bb0915","article-title":"Potential role and mechanism for high mobility group box1 in childhood chronic immune thrombocytopenia","volume":"23","author":"Wang","year":"2019","journal-title":"European Review for Medical & Pharmacological Sciences."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0920","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","article-title":"Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self","volume":"6","author":"Sakaguchi","year":"2005","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb0925","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0930","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2006.00780.x","article-title":"Abnormality of CD4+ CD25+ regulatory T cells in idiopathic thrombocytopenic purpura","volume":"78","author":"Liu","year":"2007","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0935","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.1990.tb02591.x","article-title":"In vitro suppressor T lymphocyte dysfunction in autoimmune thrombocytopenic purpura associated with a complement-fixing antibody","volume":"74","author":"Hymes","year":"1990","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0940","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.exphem.2012.01.001","article-title":"Critical role of CD4+ CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia","volume":"40","author":"Nishimoto","year":"2012","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0945","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jth.12079","article-title":"Predominant autoantibody response to GPIb\/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia","volume":"11","author":"Nishimoto","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0950","first-page":"1325","article-title":"Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura","volume":"112","author":"Yu","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0955","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"\u201cNatural\u201d killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb0960","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.2830370409","article-title":"Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura","volume":"37","author":"Semple","year":"1991","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb0965","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2015.11.005","article-title":"NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia","volume":"177","author":"Ebbo","year":"2017","journal-title":"Clin. Immunol."},{"issue":"24","key":"10.1016\/j.thromres.2024.02.005_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008415","article-title":"Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy","volume":"6","author":"Andersson","year":"2004","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.thromres.2024.02.005_bb0975","doi-asserted-by":"crossref","unstructured":"Rydyznski CE, Cranert SA, Zhou JQ, Xu H, Kleinstein SH, Singh H, et al. Affinity maturation is impaired by natural killer cell suppression of germinal centers. Cell Rep. 2018;24(13):3367\u201373. e4.","DOI":"10.1016\/j.celrep.2018.08.075"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb0980","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"25","key":"10.1016\/j.thromres.2024.02.005_bb0985","first-page":"5738","article-title":"Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1\u2013dependent mechanism that is up-regulated by interleukin-13","volume":"116","author":"Highfill","year":"2010","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb0990","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.14542","article-title":"Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells","volume":"181","author":"Aslam","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb0995","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2741\/A923","article-title":"The role of cholangiocytes in the development of chronic inflammatory liver disease","volume":"7","author":"Adams","year":"2002","journal-title":"Frontiers in Bioscience-Landmark."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1000","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.20.092501.134942","article-title":"KIR: diverse, rapidly evolving receptors of innate and adaptive immunity","volume":"20","author":"Vilches","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-065X.2001.1810105.x","article-title":"Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules","volume":"181","author":"Boyington","year":"2001","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb1010","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/bjh.16334","article-title":"Increased cytotoxic potential of CD8+ T cells in immune thrombocytopenia","volume":"188","author":"Vrbensky","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"06","key":"10.1016\/j.thromres.2024.02.005_bb1015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1160\/TH12-01-0012","article-title":"Increased plasma levels of granzymes in adult patients with chronic immune thrombocytopenia","volume":"107","author":"Olsson","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1020","doi-asserted-by":"crossref","first-page":"27445","DOI":"10.1038\/srep27445","article-title":"CD8+ T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia","volume":"6","author":"Qiu","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1025","first-page":"1078","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb1030","doi-asserted-by":"crossref","unstructured":"PO A. Reduced transforming growth factor-\u03b21 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 2002;116:862\u20137.","DOI":"10.1046\/j.0007-1048.2002.03345.x"},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb1035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1365-2141.1996.d01-1464.x","article-title":"Serum levels of GM-CSF are elevated in patients with thrombocytopenia","volume":"92","author":"Abboud","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1040","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/00043426-200312001-00002","article-title":"The etiology of childhood immune thrombocytopenic purpura: how complex is it?","volume":"25","author":"Chanock","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.thromres.2024.02.005_bb1050","doi-asserted-by":"crossref","unstructured":"Banchereau J, Dubois B, Fayette J, Burdin N, Briere F, Miossec P, et al. Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Dendritic Cells in Fundamental and Clinical Immunology: Volume 2: Springer; 1995. p. 79\u201383.","DOI":"10.1007\/978-1-4615-1971-3_16"},{"issue":"5589","key":"10.1016\/j.thromres.2024.02.005_bb1055","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1126\/science.1072615","article-title":"A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory","volume":"297","author":"Bourgeois","year":"2002","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.thromres.2024.02.005_bb1060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2174\/1568009614666140828103253","article-title":"The role of CD40 expression in dendritic cells in cancer biology; a systematic review","volume":"14","author":"Han Lee","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(97)80078-7","article-title":"Functions of CD40 on B cells, dendritic cells and other cells","volume":"9","author":"van Kooten","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0065-2776(08)60854-8","article-title":"CD40 and its ligand","volume":"63","author":"Clark","year":"1996","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0268-960X(95)90040-3","article-title":"CD40 and its ligand: central players in B lymphocyte survival, growth, and differentiation","volume":"9","author":"Gordon","year":"1995","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2024.02.005_bb1080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.005_bb1085","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/jcph.1278","article-title":"Safety, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 655064, an antagonistic anti-CD40 antibody, in healthy subjects: a potential novel treatment for autoimmune diseases","volume":"58","author":"Schwabe","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb1090","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"78","author":"Visvanathan","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2024.02.005_bb1095","doi-asserted-by":"crossref","unstructured":"Alaaeddine N, Hassan GS, Yacoub D, Mourad W. CD154: \u0438\u043c\u043c\u0443\u043d\u043e\u0432\u043e\u0441\u043f\u0430\u043b\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0439 \u043c\u0435\u0434\u0438\u0430\u0442\u043e\u0440 \u043f\u0440\u0438 \u0441\u0438\u0441\u0442\u0435\u043c\u043d\u043e\u0439 \u043a\u0440\u0430\u0441\u043d\u043e\u0439 \u0432\u043e\u043b\u0447\u0430\u043d\u043a\u0435 \u0438 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u043e\u043c \u0430\u0440\u0442\u0440\u0438\u0442\u0435. Clin. Dev. Immunol. 2012;2012:490148-.","DOI":"10.1155\/2012\/490148"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0923-2494(94)80186-X","article-title":"The role of CD40L (gp39)\/CD40 in T\/B cell interaction and primary immunodeficiency","volume":"145","author":"Ochs","year":"1994","journal-title":"Res. Immunol."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.005_bb1105","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.185.12.2053","article-title":"A new mechanism of NK cell cytotoxicity activation: the CD40\u2013CD40 ligand interaction","volume":"185","author":"Carbone","year":"1997","journal-title":"J. Exp. Med."},{"issue":"14","key":"10.1016\/j.thromres.2024.02.005_bb1110","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1182\/bloodadvances.2023009949","article-title":"Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP","volume":"7","author":"Georgi","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1115","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2024.02.005_bb1120","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1125","first-page":"395","article-title":"\u0411\u0435\u0440\u0435\u0436\u043d\u043e\u0435 \u043e\u0442\u043d\u043e\u0448\u0435\u043d\u0438\u0435 \u043a \u043a\u0440\u043e\u0432\u0438 \u0431\u043e\u043b\u044c\u043d\u043e\u0433\u043e \u043a\u0430\u043a \u043f\u0440\u0438\u043e\u0440\u0438\u0442\u0435\u0442\u043d\u0430\u044f \u0441\u0442\u0440\u0430\u0442\u0435\u0433\u0438\u044f \u0432 \u043a\u0430\u0440\u0434\u0438\u043e\u0445\u0438\u0440\u0443\u0440\u0433\u0438\u0438","volume":"66","author":"\u041a\u0443\u043f\u0440\u044f\u0448\u043e\u0432","year":"2021","journal-title":"\u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb1130","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"The Lancet Haematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb1135","doi-asserted-by":"crossref","unstructured":"Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg S. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. Journal of immunology (Baltimore, Md: 1950). 1985;134(1):157\u201366.","DOI":"10.4049\/jimmunol.134.1.157"},{"key":"10.1016\/j.thromres.2024.02.005_bb1140","first-page":"2129","article-title":"The yin and yang of interleukin-2\u2013mediated immunotherapy","author":"Bluestone","year":"2011","journal-title":"Mass Medical Soc"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1145","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cyto.b.21494","article-title":"Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia","volume":"94","author":"Zhang","year":"2018","journal-title":"Cytometry B Clin. Cytom."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cyto.b.21601","article-title":"Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: an analysis of 3 cases","volume":"94","author":"Zhang","year":"2018","journal-title":"Cytometry B Clin. Cytom."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1155","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","article-title":"Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura","volume":"148","author":"Peerschke","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2141.1985.tb07477.x","article-title":"Platelet-associated complement in chronic ITP","volume":"60","author":"Kurata","year":"1985","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb1165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb1170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis."},{"key":"10.1016\/j.thromres.2024.02.005_bb1175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1651-2227.1998.tb01231.x","article-title":"Role of complement in immune or idiopathic thrombocytopenic purpura","volume":"87","author":"Hed","year":"1998","journal-title":"Acta Paediatr."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb1180","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.thromres.2024.02.005_bb1185","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood.V124.21.1453.1453","article-title":"Classical pathway of complement activation in ITP: inhibition by TNT003, a novel C1s inhibitor","volume":"124","author":"Peerschke","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","article-title":"Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance","volume":"80","author":"Ballem","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2024.02.005_bb1195","series-title":"Cines DB","author":"Stoll","year":"1985"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb1200","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1309\/RAW2-0LQW-8YTX-941V","article-title":"Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia","volume":"115","author":"Kurata","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1205","unstructured":"Hayashi S, Nishiyama M, Suehisa E, Kashiwagi H, Kurata Y, Tomiyama Y. Comparison between two methods for the measurement reticulated platelet and their clinical significance--flow cytometry (FCM) method and IPF method Using automated hematology analyzer (XE-2000). Rinsho byori The Japanese Journal of Clinical Pathology. 2009;57(11):1039\u201344."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb1210","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","volume":"339","author":"Thrombopoietin","year":"1998","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb1215","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematology\/Oncology Clinics."},{"issue":"06","key":"10.1016\/j.thromres.2024.02.005_bb1220","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1055\/s-0037-1615023","article-title":"The diagnostic value of thrombopoietin level measurements in thrombocytopenia","volume":"79","author":"Porcelijn","year":"1998","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1225","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1230","series-title":"Meng G","author":"Emmons","year":"1996"},{"issue":"12","key":"10.1016\/j.thromres.2024.02.005_bb1235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.23562","article-title":"Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists","volume":"88","author":"Makar","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"80","author":"Kuter","year":"2008","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.005_bb1245","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.thromres.2024.02.005_bb1250","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"New England Journal of Medicine."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1255","first-page":"537","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"9664","key":"10.1016\/j.thromres.2024.02.005_bb1260","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"The Lancet."},{"issue":"9610","key":"10.1016\/j.thromres.2024.02.005_bb1265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.thromres.2024.02.005_bb1270","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"New England Journal of Medicine."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb1275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1280","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.thromres.2024.02.005_bb1285","first-page":"3887","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1290","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000510676","article-title":"Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel","volume":"144","author":"Cooper","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.thromres.2024.02.005_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100647","article-title":"Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations","volume":"41","author":"Zaja","year":"2020","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/09537104.2013.870987","article-title":"Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia","volume":"26","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Platelets"},{"issue":"04","key":"10.1016\/j.thromres.2024.02.005_bb1305","first-page":"1","article-title":"Sustained responses following treatment with romiplostim in immune thrombocytopenia: a single-Centre experience","volume":"2","author":"Provan","year":"2014","journal-title":"J Hematol Thromboembolic Dis."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb1310","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion"},{"issue":"21","key":"10.1016\/j.thromres.2024.02.005_bb1315","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/bloodadvances.2018020248","article-title":"Activity of eltrombopag in severe aplastic anemia","volume":"2","author":"Scheinberg","year":"2018","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb1320","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1325","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/path.5529","article-title":"Integrated genetic and epigenetic analysis of cancer-related genes in non-ampullary duodenal adenomas and intramucosal adenocarcinomas","volume":"252","author":"Ota","year":"2020","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1330","doi-asserted-by":"crossref","first-page":"18020","DOI":"10.1038\/s41598-020-74798-z","article-title":"Epigenetic alterations in skin homing CD4+ CLA+ T cells of atopic dermatitis patients","volume":"10","author":"Acevedo","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb1335","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/genes12050680","article-title":"Epigenetic contribution and genomic imprinting Dlk1-Dio3 miRNAs in systemic lupus erythematosus","volume":"12","author":"Dai","year":"2021","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1203\/01.pdr.0000203565.76028.2a","article-title":"Epigenetic regulation of stem cell differentiation","volume":"59","author":"Wu","year":"2006","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.thromres.2024.02.005_bb1345","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3389\/fimmu.2019.02512","article-title":"Selective histone deacetylase 6 inhibition normalizes B cell activation and germinal center formation in a model of systemic lupus erythematosus","volume":"10","author":"Ren","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.005_bb1350","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.005_bb1355","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","article-title":"The diverse roles of DNA methylation in mammalian development and disease","volume":"20","author":"Greenberg","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.005_bb1360","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.humimm.2014.09.018","article-title":"Foxp3 methylation status in children with primary immune thrombocytopenia","volume":"75","author":"Chen","year":"2014","journal-title":"Hum. Immunol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.005_bb1365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050038","article-title":"Epigenetic control of the foxp3 locus in regulatory T cells","volume":"5","author":"Floess","year":"2007","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1370","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/labmed\/lmw040","article-title":"Association of DNA methyltransferase 3B promotor polymorphism with childhood chronic immune thrombocytopenia","volume":"47","author":"Gouda","year":"2016","journal-title":"Lab. Med."},{"issue":"27","key":"10.1016\/j.thromres.2024.02.005_bb1375","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1016\/j.febslet.2006.10.061","article-title":"IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?","volume":"580","author":"Perrier","year":"2006","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.005_bb1380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gene.2012.09.024","article-title":"DNA methyltransferase 3B (DNMT3B\u2212 579 G> T) promotor polymorphism and the susceptibility to pediatric immune thrombocytopenic purpura in Egypt","volume":"511","author":"Khorshied","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.thromres.2024.02.005_bb1385","doi-asserted-by":"crossref","unstructured":"Abd-Elkader AS, ElMelegy TT, NasrEldin E, Abd-Elhafez ZA. DNA methyltransferases 3A\u2212 448 G\/A and 3B\u2212 149C\/T single-nucleotide polymorphisms in primary immune thrombocytopenia. The Egyptian Journal of Haematology. 2018;43(1):32\u20137.","DOI":"10.4103\/ejh.ejh_2_18"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1390","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.molcel.2019.08.019","article-title":"Histone modifications regulate chromatin compartmentalization by contributing to a phase separation mechanism","volume":"76","author":"Wang","year":"2019","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.thromres.2024.02.005_bb1400","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/09537104.2013.859664","article-title":"Aberrant histone methylation in the patients with immune thrombocytopenia","volume":"25","author":"Zhao","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2024.02.005_bb1405","first-page":"49","volume":"220","author":"El Bairi","year":"2018","journal-title":"Decoding colorectal cancer epigenomics. Cancer genetics."},{"issue":"9","key":"10.1016\/j.thromres.2024.02.005_bb1410","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/iub.2310","article-title":"Analysis of the expression profile of long non-coding RNAs MALAT1 and THRIL in children with immune thrombocytopenia","volume":"72","author":"Ayoub","year":"2020","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.thromres.2024.02.005_bb1415","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MBC.0000000000000069","article-title":"Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura","volume":"25","author":"Bay","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"05","key":"10.1016\/j.thromres.2024.02.005_bb1420","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1160\/TH14-04-0342","article-title":"Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia","volume":"113","author":"Zhou","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.005_bb1425","first-page":"674","article-title":"Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia","volume":"138","author":"Han","year":"2021","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"10.1016\/j.thromres.2024.02.005_bb1430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630693","article-title":"Low-dose decitabine inhibits cytotoxic T lymphocytes-mediated platelet destruction via modulating PD-1 methylation in immune thrombocytopenia","volume":"12","author":"Han","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:53:43Z","timestamp":1758736423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":286,"alternative-id":["S0049384824000392"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.005","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}